Helicobacter creates immune system blind spot

March 13, 2018, Max Planck Society
Surface of a Helicobater-infected mucosoid culture made of normal epithelial cells from the human stomach (red: Helicobacter pylori, blue: nuclei, green: cell membranes). Credit: MPI f. Infection Biology

The gastric bacterium H. pylori colonizes the stomachs of around half the human population and can lead to the development of gastric cancer. It is usually acquired in childhood and persists life-long, despite a strong inflammatory defence reaction in the gastric mucosa. Such inflammation is normally beneficial, as it kills invading pathogens and is then resolved. In the case of H. pylori, however, the inflammation never manages to eliminate the invader, and instead persists for decades – which is a driving force in the development of ulcers and cancer.

While many persistent bacteria rely on preventing immune detection, persistence in the midst of acute inflammation is a highly unusual feat for a pathogen, and so far it has been completely unclear how Helicobacter is able to do this. Now researchers at the Max Planck Institute for Infection Biology in Berlin have found that by extracting cholesterol from membranes, H. pylori breaks down a vital component needed to assemble the receptors for interferons. These cytokines are key signalling molecules for summoning the adaptive immune system to the infected mucosa – and their absence generates a niche where the bacteria can survive while the inflammation continues unabated in the surrounding area.

While gastritis and gastric ulcer disease used to be put down to stress and dietary factors, it was discovered in the 1980s that the actual culprit is infection with a bacterium, H. pylori. This pathogen is now classed as a type I carcinogen by the WHO, as it is the major risk factor for development of gastric carcinoma. Attempts to develop a vaccine against H. pylori have been unsuccessful and the new results provide the first potential explanation for these failures: H. pylori blocks the signal that would allow infected to summon help from the immune system.

Driven by their interest in understanding the mechanisms by which bacterial infections can give rise to cancer, the laboratory of Thomas F. Meyer already discovered over a decade ago that H. pylori expresses an enzyme called cholesterol-α-glucosyltransferase to extract the cholesterol it needs from host cells. Without this enzyme, the bacteria are unable to infect mice. At the time, the group also noted that excess cholesterol in the diet of the mice enhanced clearance of the pathogen but exacerbated inflammation. Exactly how the ability to extract cholesterol was linked to immune evasion remained unclear at the time.

Helicobacter creates immune system blind spot
Extraction of cholesterol from host cells allows Helicobacter bacteria to generate protected niches of cells in which normal signaling pathways for recruiting immune cells are blocked. Credit: MPI f. Infection Biology

Now, new technologies for growing primary stomach cells in vitro have been instrumental for solving this puzzle. Meyer's laboratory succeeded in reconstituting the mucosal epithelium of the stomach, yielding so-called "mucosoids" in which gastric cells grow as monolayers with an outer and an inner surface and even produce the mucus that lines and protects the stomach. As a result, the infected "mini-organs" could be kept alive for months.

Cholesterol is required for lipid raft formation

Infected gastric epithelial cells normally summon immune cells and generate antimicrobial factors that kill the bacteria. This response depends on a crucial immune signaling factor produced by epithelial cells: interferon-γ. Using the mucosoid model, the group found that the bacteria survive as small micro-colonies on top of cells. This turned out to be due to the absence of so-called "lipid rafts" in the cell membranes, which are required for assembly of interferon receptor complexes. Without these, host cells simply did not respond to interferon-γ at all. The lipid rafts are made of cholesterol, and their destruction is mediated by the bacterium's cholesterol-α-glucosyltransferase.

"Showing how H. pylori persists in the midst of an explains a whole series of observations that have puzzled researchers for decades and has caused us to think of the infection scenario in an entirely new light" says Pau Morey, first author of the study. Francesco Boccellato, who developed the new in vitro model adds: "the mucosoids enable long-term, stable infections to be investigated – and will be an invaluable tool for examining the mechanisms underlying mucosal infections, the mucosal defence and the emergence of cancer."

Explore further: How Helicobacter pylori causes gastric cancer

More information: Pau Morey et al. Helicobacter Pylori Depletes Cholesterol in Gastric Glands to Prevent Interferon Gamma Signaling and Escape the Inflammatory Response, Gastroenterology (2017). DOI: 10.1053/j.gastro.2017.12.008

Francesco Boccellato et al. Polarised epithelial monolayers of the gastric mucosa reveal insights into mucosal homeostasis and defence against infection, Gut (2018). DOI: 10.1136/gutjnl-2017-314540

Related Stories

How Helicobacter pylori causes gastric cancer

November 7, 2017
Gastric cancer is one of the five most fatal types of cancer. According to the statistics of the World Health Organization (WHO), about 750,000 patients die each year after developing the disease. The main cause is thought ...

Stomach bacteria switch off human immune defences to cause disease

September 1, 2013
Helicobacter pylori is a bacterium that establishes a life-long stomach infection in humans, which in some cases can lead to duodenal ulcers or stomach cancer. New research, presented at this week's Society for General Microbiology ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.